Tag: aromataseInhibitors
Aromatase inhibitors: Drugs designed to inhibit the action of the enzyme aromatase, which converts androgens into estrogens within the body. Aromatase inhibitors are a type of first-line endocrine treatment for estrogen receptor positive (ER+) breast cancer.
Articles
News
08/26/17
Walking can reduce aromatase inhibitor-induced joint pain 01/12/15
Early birth control pill use is linked to recurrence of premenopausal breast cancer 09/08/13
Not completing anti-estrogen treatment linked to sharply higher risk of recurrence 04/30/13
Unpleasant side effects of anti-estrogens can indicate treatment is working 12/31/12
Treatment with Femara after tamoxifen can worsen cholesterol profile 07/19/12
Aromatase inhibitors are less effective in reducing estrogen in women with high BMI 07/15/12
Reduction in breast density shows endocrine treatment is working 03/08/12
Heart drug digoxin (digitalis) increases risk of breast cancer 02/06/12
Soy supplements do not reduce breast cancer risk and could be harmful 01/12/12
How much red wine is safe for breast cancer survivors? 10/19/11
Tumor response to anti-estrogen treatment before surgery is influenced by BMI and race 09/07/11
Strongly estrogen positive lobular breast cancer responds well to neoadjuvant Femara 08/17/11
Genistein stimulates aromatase activity and ER+ breast cancer cell growth 07/31/11
High dose vitamin D reduces musculoskeletal symptoms in women taking Arimidex 07/17/11
Increasingly severe side effects of aromatase inhibitors may make tamoxifen first the best strategy 07/09/11
Vitamin D supplementation might interfere with aromatase inhibitor treatment 06/09/11
Patients with ER-/PR+ breast cancer benefit from endocrine therapy 03/23/11
Obesity increases inflammation and estrogen production in breast tissue 03/01/11
Aromatase inhibitor only or after tamoxifen are both effective treatments 11/18/10
Aromatase inhibitors have numerous side effects in addition to musculoskeletal symptoms 07/19/10
Women with high BMI may benefit less from hormonal treatments 06/12/10
Cognitive function improves after completion of both Femara and tamoxifen treatment 03/07/10
Weight gain can increase hot flashes in breast cancer survivors on aromatase inhibitors 02/20/10
Vitamin D deficiency promotes growth of breast cancer bone metastases 02/13/10
Tamoxifen treatment results in cognitive impairment compared to Aromasin 01/22/10
Treatment with aromatase inhibitors results in better breast cancer outcomes than tamoxifen
Studies
Breast cancer survival, survival disparities, and guideline-based treatment Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27 Metabolomics Reveals that Dietary Xenoestrogens Alter Cellular Metabolism Induced by Palbociclib/Letrozole Combination Cancer Therapy Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27 The occurrence of fractures after adjuvant treatment of breast cancer: a DBCG register study Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis Vascular function in breast cancer survivors on aromatase inhibitors: a pilot study Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05) Long-Term Follow-Up of the Intergroup Exemestane Study Randomized Controlled Trial of a Home-Based Walking Program to Reduce Moderate to Severe Aromatase Inhibitor-Associated Arthralgia in Breast Cancer Survivors Challenges of measuring accurate estradiol levels in aromatase inhibitor-treated postmenopausal breast cancer patients on vaginal estrogen therapy Premenopausal women with early breast cancer treated by estradiol suppression have severely deteriorated bone microstructure Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study Treatment Restarting After Discontinuation of Adjuvant Hormone Therapy in Breast Cancer Patients Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study Comparison of the Effects of Nobiletin and Letrozole on the Activity and Expression of Aromatase in MCF-7 Breast Cancer Cell Line Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in Postmenopausal Women with Hormone Sensitive Breast Cancer: Joint Position Statement of the IOF, CABS, ECTS, IEG, ECCEO and IMS 7-hydroxycholesterol induces invasion and migration of breast cancer cells by increasing MMP9 and generating EMT through activation of STAT-3 Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04) The effect of exercise on body composition and bone mineral density in breast cancer survivors taking aromatase inhibitors Cardiotoxicity of Aromatase Inhibitors and Tamoxifen in Post-Menopausal Women with Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Aromatase inhibitors and endothelial function: Is there an association with early cardiovascular disease? Bone remodeling and regulating biomarkers in women at the time of breast cancer diagnosis Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) Body mass index and menopausal disorders during menopause affect vasomotor symptoms of postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes Memory and Spatial Cognition in Breast Cancer Patients Undergoing Adjuvant Endocrine Therapy Estrogens - the Saviors of Cognitive Function? Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer Effective Hormone Therapy Reduces the Efficacy of Subsequent Chemotherapy in Hormone-Receptor-Positive Metastatic Breast Cancer Treatment with aromatase inhibitors and markers of cardiovascular disease Prognostic value of endocrine treatment-related symptoms in patients with breast cancer: a meta-analysis Estrogen Receptor Activation by Tobacco Smoke Condensate in Hormonal Therapy-Resistant Breast Cancer Cells Antihormonal treatment associated musculoskeletal pain in women with breast cancer in the adjuvant setting Is it best to expect the worst? Influence of patients' side-effect expectations on endocrine treatment outcome in a 2-year prospective clinical cohort study Longitudinal changes in volumetric breast density with adjuvant endocrine therapy among women with breast cancer Weight gain during adjuvant endocrine treatment for early-stage breast cancer: What is the evidence? Aromatase inhibitors decrease radiation-induced lung fibrosis: Results of an experimental study Ocular Surface Disease in Breast Cancer Patients Using Aromatase Inhibitors Differential profile of letrozole and exemestane on bone turnover markers in vinyl cyclohexene diepoxide treated ovotoxic female mice Impacts of smoking on endocrine treatment response in a prospective breast cancer cohort Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years Effects of vitamin D and calcium supplementation on side effects profile in patients of breast cancer treated with letrozole Periodontal Health in Breast Cancer Patients on Aromatase Inhibitors vs. Postmenopausal Controls: A longitudinal Analysis Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trial Current issues in adjuvant hormonal therapy for early breast cancer Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions Impact of physical activity/exercise on adverse events and quality of life during treatment with everolimus and exemestane for ER+ women - Results of the 3rd interim analysis of BRAWO The effect of aromatase inhibitor therapy on the cardiovascular health of black and white breast cancer patients Male breast cancer is not congruent with the female disease Exemestane use in postmenopausal women at high risk for invasive breast cancer: evaluating biomarkers of efficacy and safety Large-scale Survey of the Impact of Complementary Medicine on Side-effects of Adjuvant Hormone Therapy in Patients with Breast Cancer Patient-reported outcome (PRO) results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) vs tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy Alcohol Regulates Genes that Are Associated with Response to Endocrine Therapy and Attenuates the Actions of Tamoxifen in Breast Cancer Cells The Impact of Endocrine Therapy on Cognitive Functions of Breast Cancer Patients: A Systematic Review Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity A phase II trial of low-dose estradiol in postmenopausal women with advanced breast cancer and acquired resistance to aromatase inhibition Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial Aromatase inhibitor induced musculoskeletal syndrome: a significant problem with limited treatment options Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy Endocrine resistance in breast cancer - an overview and update Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial Impact of aromatase inhibitor treatment on vertebral morphology and bone mineral density in postmenopausal women with breast cancer Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance Can Exercise Ameliorate Aromatase Inhibitor-Induced Cognitive Decline in Breast Cancer Patients? Aromatase overexpression in dysfunctional adipose tissue links obesity to postmenopausal breast cancer Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy Joint symptoms and health-related quality of life in postmenopausal women with breast cancer who completed 5 years of anastrozole Arthralgia among women taking aromatase inhibitors: is there a shared inflammatory mechanism with co-morbid fatigue and insomnia? Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ Fracture Risk and Adjuvant Therapies in Young Breast Cancer Patients: A Population-Based Study A nude mouse model of obesity to study the mechanisms of resistance to aromatase inhibitors Neoadjuvant chemotherapy with or without the concurrent hormone therapy that has downregulated estrogen level in estrogen receptor positive breast cancer: NACED randomized multicenter phase II trial Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer Locoregional and Overall Recurrence After Neaodjuvant Endocrine Therapy Versus Chemotherapy in Postmenopausal Women With Estrogen Receptor+ HER2- Breast Cancer Aromatase inhibitor induced musculoskeletal syndrome (AIMSS) in Australian women with early breast cancer: An Australia and New Zealand Breast Cancer Trials Group (ANZBCTG) survey of members of the Breast Cancer Network Australia (BCNA) Effects of Chemotherapy and Hormone Therapy on Biomarkers of Cardiac Injury and Oxidative Stress in Women with Breast Cancer Factors Associated with Anastrozole-Induced Musculoskeletal Adverse Effects in Post-menopausal Breast Cancer Women: A Preliminary Report Aromatase inhibitors in male breast cancer: a pooled analysis Fracture incidence in pre- and postmenopausal women after completion of adjuvant hormonal therapy for breast cancer Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial History of oral contraceptive use in breast cancer patients: impact on prognosis and endocrine treatment response Interaction of Salicylates and the Other Nonsteroidal Anti-Inflammatory Agents With Breast Cancer Endocrine Treatment: Systematic Review Randomized Exercise Trial of Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors Bisphosphonates May Protect against Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Aromatase Inhibitor Therapy: Results from a Meta-analysis Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial Cognitive Function After the Initiation of Adjuvant Endocrine Therapy in Early-Stage Breast Cancer: An Observational Cohort Co-administrating luteolin minimizes the side effects of the aromatase inhibitor letrozole Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptor-positive breast cancer: a systematic review Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials. Modification of Abdominal Fat Distribution After Aromatase Inhibitor Therapy in Breast Cancer Patients Visualized Using 3-D Computed Tomography Volumetry Racial disparities in initiation of adjuvant endocrine therapy of early breast cancer Primary endocrine therapy as a treatment for older women with operable breast cancer - A comparison of randomised controlled trial and cohort study findings A Pilot Study Comparing the Effect of Flaxseed, Aromatase Inhibitor, and the Combination on Breast Tumor Biomarkers Long-Term Outcome of Neoadjuvant Endocrine Therapy with Aromatase Inhibitors in Elderly Women with Hormone Receptor-Positive Breast Cancer Exercise intervention in breast cancer patients with aromatase inhibitor-associated arthralgia: a pilot study High-Dose Eicosapentaenoic Acid and Docosahexaenoic Acid Supplementation Reduces Bone Resorption in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors: A Pilot Study Alopecia With Endocrine Therapies in Patients With Cancer A Survey of Joint and Muscle Aches, Pain, and Stiffness Comparing Women With and Without Breast Cancer Extra virgin olive oil potentiates the effects of aromatase inhibitors via glutathione depletion in estrogen receptor-positive human breast cancer (MCF-7) cells Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness--a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer A nested case-control study of adjuvant hormonal therapy persistence and compliance, and early breast cancer recurrence in women with stage I-III breast cancer Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer Prognostic value of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 blood levels in breast cancer The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer Specific Adverse Events Predict Survival Benefit in Patients Treated With Tamoxifen or Aromatase Inhibitors: An International Tamoxifen Exemestane Adjuvant Multinational Trial Analysis Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort Phytoestrogens in menopausal supplements induce ER-dependent cell proliferation and overcome breast cancer treatment in an in vitro breast cancer model Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality Meta-analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase inhibitors in postmenopausal women Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27A Randomized Controlled Phase III Trial Is basic research providing answers if adjuvant anti-estrogen treatment of breast cancer can induce cognitive impairment? Prevalence and risk factors for insomnia among breast cancer patients on aromatase inhibitors Synergistic effects of exemestane and aspirin on mcf-7 human breast cancer cells Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an NCIC CTG MA.17 sub-study The citrus flavonone hesperetin prevents letrozole-induced bone loss in a mouse model of breast cancer Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 Trial Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index Aromatase inhibitors in obese breast cancer patients are not associated with increased plasma estradiol levels Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole Comparison of the effects of aromatase inhibitors and tamoxifen on radiation-induced lung toxicity: results of an experimental study Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients Suppression of Plasma Estrogen Levels by Letrozole and Anastrozole Is Related to Body Mass Index in Patients With Breast Cancer Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone Postmenopausal Women with DCIS Post-Mastectomy: A Potential Role for Aromatase Inhibitors Impact of obesity in postmenopausal early breast cancer patients receiving frontline adjuvant aromatase inhibitors Risk factors for fractures in patients on hormonal therapies for breast cancer and DCIS Aromatase inhibitors and cardiac outcomes in women undergoing cardiac angiography after early breast cancer Prognostic implications of estrogen receptor pattern of both tumors in contralateral breast cancer Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation Vitamin D threshold to prevent aromatase inhibitor-related bone loss: the B-ABLE prospective cohort study Eligibility, compliance and persistence of extended adjuvant endocrine therapy for breast cancer Molecular Pathways: Digoxin use and the estrogen-sensitive cancers: risks and possible therapeutic implications Tamoxifen and Anastrozole As a Sequencing Strategy: A Randomized Controlled Trial in Postmenopausal Patients With Endocrine-Responsive Early Breast Cancer From the Austrian Breast and Colorectal Cancer Study Group Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast Cancer Effects of Vaginal Estrogens on Serum Estradiol Levels in Postmenopausal Breast Cancer Survivors and Women at Risk of Breast Cancer Taking an Aromatase Inhibitor or a Selective Estrogen Receptor Modulator Deep Time: The Long and the Short of Adjuvant Endocrine Therapy for Breast Cancer Patient-Reported Predictors of Early Treatment Discontinuation: NCIC JMA.27/E1Z03 Quality of Life Study of Postmenopausal Women with Primary Breast Cancer Randomized to Exemestane or Anastrozole Red Versus White Wine as a Nutritional Aromatase Inhibitor in Premenopausal Women Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole Serum leptin level and waist-to-hip ratio (WHR) predict the overall survival of metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs) The Protective Effect of Zoledronic Acid on Bone Loss in Postmenopausal Women with Early Breast Cancer Treated with Sequential Tamoxifen and Letrozole: A Prospective, Randomized, Phase II Trial Aromatase Inhibitors as Solely Treatment in Postmenopausal Breast Cancer Patients Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle Induced sex reversal using an aromatase inhibitor, Fadrozole, in Atlantic halibut (Hippoglossus hippoglossus L.) Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy Hormone Treatment without Surgery for Patients Aged 75 Years or Older with Operable Breast Cancer Androgen receptor genotypes predict response to endocrine treatment in breast cancer patients Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer Association between race and BMI with response to neoadjuvant endocrine therapy in postmenopausal women with large estrogen receptor-positive breast cancers Final 5-year results of Z-FAST trial: Adjuvant Zoledronic Acid Maintains Bone Mass in Postmenopausal Breast Cancer Patients Receiving Letrozole Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07) Management of Hot Flashes in Patients Who Have Breast Cancer With Venlafaxine and Clonidine: A Randomized, Double-Blind, Placebo-Controlled Trial Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients Mortality Rates Among Early-Stage Hormone Receptor-Positive Breast Cancer Patients: A Population-Based Cohort Study in Denmark Invasive lobular carcinoma: response to neoadjuvant letrozole therapy Genistein induces breast cancer-associated aromatase and stimulates estrogen-dependent tumor cell growth in in vitro breast cancer model The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work? Influence of histology on the effectiveness of adjuvant chemotherapy in patients with hormone receptor positive invasive breast cancer An analysis of vitamin D (Vit D) and serum estrogens in postmenopausal (PM) breast cancer (BC) patients receiving aromatase inhibitors (AIs) Effect of change of body mass index (BMI) during therapy on the efficacy of endocrine therapy in premenopausal patients with breast cancer: An analysis of the ABCSG-12 trial Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis Obesity Is Associated with Inflammation and Elevated Aromatase Expression in the Mouse Mammary Gland Cancer Therapy Associated Bone Loss: Implications for Hip Fractures in Mid-Life Women with Breast Cancer Vitamin D Deficiency in Post-Menopausal Breast Cancer Survivors Side effects associated with aromatase inhibitor treatment among breast cancer patients Risk of second breast cancer according to estrogen receptor status and family history Sexual Function after Breast Cancer Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial Breast cancer in the very elderly: Staging, treatment, and outcomes in patients over age 80 Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in ER-positive breast cancer Aromatase inhibitor and tamoxifen's impact on breast cancer recurrence among survivors in a large HMO Effect of early discontinuation and nonadherence to adjuvant hormone therapy on mortality in women with breast cancer Changes in cognitive function in postmenopausal women 1 year after completing adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial Weight gain is associated with increased risk of hot flashes in breast cancer survivors on aromatase inhibitors Effects of Tamoxifen and Exemestane on Cognitive Functioning of Postmenopausal Patients With Breast Cancer: Results From the Neuropsychological Side Study of the Tamoxifen and Exemestane Adjuvant Multinational Trial The prognostic significance of single hormone receptor positive metastatic breast cancer: An analysis of three randomised phase III trials of aromatase inhibitors Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study HDAC inhibitors trigger the autophagic switch from prosurvival to prodeath in tamoxifen-treated breast cancer cells Effect of aromatase inhibitors on lipid metabolism, inflammatory response and antioxidant balance in patients with breast carcinoma Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer
TOP